Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Mol Imaging Radionucl Ther ; 31(2): 145-147, 2022 Jun 27.
Article in English | MEDLINE | ID: mdl-35771035

ABSTRACT

A 77-year-old woman with follicular thyroid cancer underwent total thyroidectomy and subsequent Iodine-131 remnant ablation. She had a history of a wide tenosynovial giant cell tumor (TGCT) of the right wrist and hand that had been resected thirteen years ago. Post-therapeutic scintigraphy and single photon emission computed tomography showed mild uptake on the distal right forearm, wrist and hand. Magnetic resonance imaging and posterior histopathology confirmed a relapse of TGCT. No radioiodine adverse effects were reported after a one-year follow-up. As far as we know, this report is the first in the literature to a TGCT visualized on post-therapy radioiodine scan.

2.
Eur J Nucl Med Mol Imaging ; 48(3): 786-793, 2021 03.
Article in English | MEDLINE | ID: mdl-32936372

ABSTRACT

PURPOSE: Spain has been one of the most affected countries by the COVID-19 pandemic, being among the countries with worse numbers, including the death rate. However, most patients are asymptomatic, although they are very contagious. The objective of this study was to investigate the incidence in oncological patients infected with SARS-CoV-2 that are asymptomatic for COVID-19 and at home and that undergo PET/CT for oncologic indications, nonrelated to COVID-19, finding in the PET/CT lung alterations that are suggestive of SARS-CoV-2 infection. METHODS: During the period of maximum incidence of the global pandemic in one of the most affected regions of Spain, there were 145 patients that met inclusion and exclusion criteria and were included in the study. Imaging findings previously described such as ground-glass opacities with low [18F]-FDG uptake were considered images suspicious for SARS-CoV-2 infection. Patients with these findings were referred to RT-PCR testing and close follow-up to confirm the presence or absence of COVID-19. RESULTS: Suspicious lung imaging findings were present in 7 of 145 patients (4.8%). Five of these 7 patients were confirmed as presenting SARS-CoV-2 infection, this is, COVID-19. In the remaining two, it was not possible to confirm the presence of COVID-19 with RT-PCR, although in one of them, PET/CT allowed an early diagnosis of a lung infection related to a bacterial pneumonic infection that was promptly and adequately treated with antibiotics. CONCLUSION: These results confirm that the prevalence of SARS-CoV-2 infection is higher than suspected and that there are asymptomatic patients that are attending imaging departments to be explored for their baseline oncologic processes. In these patients, PET/CT allows an early diagnosis of COVID-19.


Subject(s)
Asymptomatic Infections , COVID-19 , Fluorodeoxyglucose F18/administration & dosage , Neoplasms/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Female , Humans , Male , Neoplasms/epidemiology , Pandemics , SARS-CoV-2 , Spain/epidemiology
3.
Clin Nucl Med ; 45(8): 652-653, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32520507

ABSTRACT

We present an asymptomatic 70-year-old man referred for an F-FDG PET/CT for initial staging of a Hodgkin lymphoma. F-FDG PET/CT showed bilateral cervical lymphadenopathy (stage II). Incidentally, the CT demonstrated bilateral ground-glass opacities with low-grade F-FDG activity. CT findings were suspicious for COVID-19 pneumonitis. The COVID-19 reverse transcriptase polymerase chain reaction (RT-PCR) examination result was negative. Given the high clinical suspicion for COVID-19, the patient was isolated and repeat RT-PCR was positive at 72 hours. RT-PCR may be falsely negative in early COVID-19 disease, even with positive CT findings.


Subject(s)
Betacoronavirus , Coronavirus Infections/diagnostic imaging , Hodgkin Disease/complications , Pneumonia, Viral/diagnostic imaging , Aged , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Fluorodeoxyglucose F18 , Humans , Male , Pandemics , Pneumonia, Viral/complications , Positron Emission Tomography Computed Tomography , SARS-CoV-2
4.
Rev Esp Med Nucl Imagen Mol ; 34(5): 303-13, 2015.
Article in English, Spanish | MEDLINE | ID: mdl-26099942

ABSTRACT

The new diagnostic criteria for Alzheimer's disease (AD) acknowledges the interest given to biomarkers to improve the specificity in subjects with dementia and to facilitate an early diagnosis of the pathophysiological process of AD in the prodromal or pre-dementia stage. The current availability of PET imaging biomarkers of synaptic dysfunction (PET-FDG) and beta amyloid deposition using amyloid-PET provides clinicians with the opportunity to apply the new criteria and improve diagnostic accuracy in their clinical practice. Therefore, it seems essential for the scientific societies involved to use the new clinical diagnostic support tools to establish clear, evidence-based and agreed set of recommendations for their appropriate use. The present work includes a systematic review of the literature on the utility of FDG-PET and amyloid-PET for the diagnosis of AD and related neurodegenerative diseases that occur with dementia. Thus, we propose a series of recommendations agreed on by the Spanish Society of Nuclear Medicine and Spanish Society of Neurology as a consensus statement on the appropriate use of PET imaging biomarkers.


Subject(s)
Dementia/diagnostic imaging , Neurodegenerative Diseases/diagnostic imaging , Neuroimaging/methods , Positron-Emission Tomography/methods , Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides/analysis , Aniline Compounds , Biomarkers , Brain Chemistry , Carbon Radioisotopes , Early Diagnosis , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Radiopharmaceuticals , Thiazoles
5.
J Nucl Med ; 52(6): 865-72, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21571807

ABSTRACT

UNLABELLED: We have investigated dual-time-point (18)F-FDG PET for the detection and delineation of high-grade brain tumors using quantitative criteria applied on a voxel basis. METHODS: Twenty-five patients with suspected high-grade brain tumors and inconclusive MRI findings underwent (11)C-methionine PET and dual-time-point (18)F-FDG PET. Images from each subject were registered and spatially normalized. Parametric maps of standardized uptake value (SUV) and tumor-to-normal gray matter (TN) ratio for each PET image were obtained. Tumor diagnosis was evaluated according to 4 criteria comparing standard and delayed (18)F-FDG PET images: any SUV increase, SUV increase greater than 10%, any TN increase, and TN increase greater than 10%. Voxel-based analysis sensitivity was assessed using (11)C-methionine as a reference and compared with visual and volume-of-interest analysis for dual-time-point PET images. Additionally, volumetric assessment of the tumor extent that fulfills each criterion was compared with the volume defined for (11)C-methionine PET. RESULTS: The greatest sensitivity for tumor identification was obtained with any increase of TN ratio (100%), followed by a TN increase greater than 10% (96%), any SUV increase (80%), and an SUV increase greater than 10% (60%). These values were superior to visual analysis of standard (18)F-FDG (sensitivity, 40%) and delayed (18)F-FDG PET (sensitivity, 52%). Volume-of-interest analysis of dual-time-point PET reached a sensitivity of only 64% using the TN increase criterion. Regarding volumetry, voxel-based analysis with the TN ratio increase as a criterion, compared with (11)C-methionine PET, detected 55.4% of the tumor volume, with the other criteria detecting volumes lower than 20%. Nevertheless, volume detection presented great variability, being better for metastasis (78%) and glioblastomas (56%) than for anaplastic tumors (12%). A positive correlation was observed between the volume detected and the time of acquisition of the delayed PET image (r = 0.66, P < 0.001), showing volumes greater than 75% when the delayed image was obtained at least 6 h after (18)F-FDG injection. CONCLUSION: Compared with standard (18)F-FDG PET studies, quantitative dual-time-point (18)F-FDG PET can improve sensitivity for the identification and volume delineation of high-grade brain tumors.


Subject(s)
Brain Neoplasms/diagnostic imaging , Fluorodeoxyglucose F18 , Radiopharmaceuticals , Adolescent , Adult , Aged , Brain/diagnostic imaging , Brain Neoplasms/pathology , Child , Female , Glioblastoma/diagnostic imaging , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Methionine , Middle Aged , Radionuclide Imaging , Young Adult
6.
Cardiovasc Intervent Radiol ; 33(3): 523-31, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19841973

ABSTRACT

We evaluated the feasibility, safety, and efficacy of radioembolization (administered from one or two vascular points) after the redistribution of arterial blood flow in the liver in patients with hepatic neoplasms and arterial anatomic peculiarities (AAP). Twenty-four patients with liver neoplasms and AAP (graded according to Michel's classification) were included in the study. During pretreatment angiographic planning, all extrahepatic vessels that could feed the tumor were embolized and the intrahepatic vessels occluded in order to redistribute blood flow. The distribution of microspheres was initially assessed by using technetium-99m-labeled macroaggregated albumin ((99m)Tc-MAA) from one of two vascular points before the administration of yttrium-90 ((90)Y)-radiolabeled resin microspheres. Perfusion of lesions situated in the redistributed segments (L-RS) and nonredistributed segments (L-NRS) were compared by assessing the distribution of (99m)Tc-MAA by SPECT/CT. Perfusion was graded as normal, reduced, or absent. (90)Y resin microspheres were then injected from the same arterial sites as (99m)Tc-MAA and the tumor response recorded 3 months later. The tumor response in L-RS was compared with that in L-NRS and graded as better, similar, or worse. Among 11 patients with type I AAP in whom mainly vessels in segments I-III or IV were occluded, perfusion of L-RS was graded as similar (n = 7) or reduced (n = 4). Among the remaining 13 patients with AAP types III (n = 3), V (n = 4), VIII (n = 3), and others (n = 3) in which aberrant arteries were occluded, perfusion of L-RS was graded as similar (n = 9), reduced (n = 3), or absent (n = 1). Overall, (99m)Tc-MAA was present in the L-RS of 95.8% patients and the distribution of (99m)Tc-MAA in L-RS and L-NRS were graded as similar in 66.6% of patients. Compared with lesions in the L-NRS, tumor response in L-RS was similar in 23 cases and worse in 1 case. No complications were recorded after the administration of (90)Y resin microspheres. Redistribution of flow in L-RS is feasible and enables a safe and effective delivery of (90)Y resin microspheres that are able to be distributed via intrahepatic collaterals and access the microvasculature of L-RS.


Subject(s)
Embolization, Therapeutic/methods , Liver Neoplasms/radiotherapy , Yttrium Radioisotopes/therapeutic use , Aged , Angiography , Feasibility Studies , Female , Humans , Liver Neoplasms/blood supply , Liver Neoplasms/diagnostic imaging , Male , Microspheres , Middle Aged , Radiography, Interventional , Radiopharmaceuticals/therapeutic use , Retrospective Studies , Safety , Technetium Tc 99m Aggregated Albumin/therapeutic use , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed
7.
Mol Imaging Biol ; 12(2): 210-7, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19543774

ABSTRACT

PURPOSE: The purpose of this study was to evaluate a dual tracer 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) and (11)C-choline positron emission tomography (PET) protocol in the detection of biochemical prostate cancer relapse. PROCEDURES: Seventy-three patients (median Prostate Specific Antigen (PSA) Test value 2.7 ng/ml (1.1-5.4)) after radical treatment. PET scans were performed by means of a ECAT-Exact HR+ in the first 18 patients and in a PET/computed tomography Biograph II in the remaining 55 patients. RESULTS: The sensitivity of (11)C-choline and FDG was 60.6% and 31%. In PSA levels over 1.9 ng/ml, sensitivity increased to 80% and 40%, respectively. In the group receiving adjuvant hormone therapy, the diagnostic yields were 71.2% and 43%, respectively. While (11)C-choline-PET could not differentiate well and poorly differentiated Gleason score patients, FDG-PET results were almost significant (p = 0.058). CONCLUSIONS: A PSA value higher than 1.9 ng/ml determines a significant increase in the diagnostic yield. Adjuvant hormonotherapy has no influence on the PET results. FDG has a better correlation with the Gleason score than (11)C-choline.


Subject(s)
Choline , Fluorodeoxyglucose F18 , Neoplasm Recurrence, Local/diagnostic imaging , Positron-Emission Tomography , Prostate-Specific Antigen/blood , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/therapy , Adult , Aged , Carbon Radioisotopes , Humans , Male , Middle Aged , Prostatic Neoplasms/blood
8.
Trends Pharmacol Sci ; 30(8): 387-96, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19595466

ABSTRACT

Two types of adipose tissue can be distinguished histologically and functionally: white (WAT) and brown adipose tissue (BAT). Whereas BAT is specialized in the production of heat, WAT stores excess energy as triacylglycerols. BAT is present throughout life in rodents, whereas in humans it was thought to involute rapidly postnatally, having essentially disappeared within the first years after birth. However, positron emission tomography has provided evidence that adults retain metabolically active BAT depots that can be induced in response to cold and sympathetic nervous system activation. These findings together with the recent identification of specific molecular determinants (PRDM16 and BMP7) activating brown adipogenesis highlights BAT as a potential relevant target for pharmacological and gene expression manipulation to combat human obesity.


Subject(s)
Adipose Tissue, Brown/metabolism , Adipose Tissue, Brown/physiology , Obesity/drug therapy , Adipogenesis/physiology , Adipose Tissue, Brown/diagnostic imaging , Adipose Tissue, White/physiology , Animals , Anti-Obesity Agents/pharmacology , Anti-Obesity Agents/therapeutic use , Bone Morphogenetic Protein 7/metabolism , Cold Temperature , DNA-Binding Proteins/metabolism , Drug Delivery Systems , Humans , Models, Biological , Obesity/metabolism , Obesity/physiopathology , Positron-Emission Tomography/methods , Sympathetic Nervous System/physiology , Transcription Factors/metabolism
9.
Dig Dis ; 27(2): 164-9, 2009.
Article in English | MEDLINE | ID: mdl-19546555

ABSTRACT

The use of external beam radiation therapy for primary treatment of hepatocellular carcinoma (HCC) has been limited by the low radiation tolerance of the non-tumoral liver. However, technical advances allowing partial liver volume external irradiation have resulted in consistently high response rates. Internal radiation therapy, also called (90)Y radioembolization ((90)Y-RE), consists in delivering implantable microspheres labeled with (90)Y into the arteries that feed liver tumors in order to provide a high dose of radiation to tumor nodules irrespective of their number, size and location, while preserving the non-tumoral liver tissue from receiving a harmful level of radiation. Among patients with HCC, (90)Y-RE is used for those that have a preserved liver function and unresectable tumors that cannot be treated with percutaneous ablation. Although (90)Y-RE is by and large well tolerated, it may produce relevant toxic effects as a result of radiation of non-target organs including cholecystitis, gastrointestinal ulceration, pneumonitis, and most importantly, liver toxicity. A significant effect on tumor growth in the treated lesions is consistently observed with disease control rates in excess of 80%. Also, (90)Y-RE may allow downstaging large or multiple lesions to radical treatments with curative intent. When compared with the survival of HCC patients in advanced stage either not treated or treated with ineffective systemic agents, survival after (90)Y-RE is encouraging and warrants future clinical trials. Clinical research in combining the cytotoxic effect of (90)Y with the cytostatic mechanism of targeted therapies is currently in progress and will provide valuable safety and toxicity data that may translate into improved clinical outcome and overall survival.


Subject(s)
Carcinoma, Hepatocellular/radiotherapy , Embolization, Therapeutic , Liver Neoplasms/radiotherapy , Yttrium Radioisotopes/therapeutic use , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...